TY - JOUR A1 - Schmitt, Jana A1 - Keller, Andreas A1 - Nourkami-Tutdibi, Nasenien A1 - Heisel, Sabrina A1 - Habel, Nunja A1 - Leidinger, Petra A1 - Ludwig, Nicole A1 - Gessler, Manfred A1 - Graf, Norbert A1 - Berthold, Frank A1 - Lenhof, Hans-Peter A1 - Meese, Eckart T1 - Autoantibody Signature Differentiates Wilms Tumor Patients from Neuroblastoma Patients JF - PLoS ONE N2 - Several studies report autoantibody signatures in cancer. The majority of these studies analyzed adult tumors and compared the seroreactivity pattern of tumor patients with the pattern in healthy controls. Here, we compared the autoimmune response in patients with neuroblastoma and patients with Wilms tumor representing two different childhood tumors. We were able to differentiate untreated neuroblastoma patients from untreated Wilms tumor patients with an accuracy of 86.8%, a sensitivity of 87.0% and a specificity of 86.7%. The separation of treated neuroblastoma patients from treated Wilms tumor patients' yielded comparable results with an accuracy of 83.8%. We furthermore identified the antigens that contribute most to the differentiation between both tumor types. The analysis of these antigens revealed that neuroblastoma was considerably more immunogenic than Wilms tumor. The reported antigens have not been found to be relevant for comparative analyses between other tumors and controls. In summary, neuroblastoma appears as a highly immunogenic tumor as demonstrated by the extended number of antigens that separate this tumor from Wilms tumor. KW - Heparan-sulfate KW - N-Myc KW - Serum autoantibodies KW - Suppressors EXT1 KW - Neuro-blastoma KW - Allelic loss KW - Lung-cancer KW - Children KW - Amplification KW - Therapy Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133794 VL - 6 IS - 12 ER -